{"entity":{"id":"nct05020015","kind":"trial","name":"A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)","aka":[],"tldr":"A phase 2 trial of TAK-007 in non-Hodgkin lymphoma, run by Takeda, active and no longer recruiting.","summary":"A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) is a phase 2 interventional study registered as NCT05020015 by Takeda, with 27 participants enrolled, started 2021-11-12 and due to reach its primary completion in 2024-06-16. Interventions recorded: TAK-007 and Chemotherapy Agents. Results have been posted on the registry.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT05020015","url":"https://clinicaltrials.gov/study/NCT05020015"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["takeda"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05020015","phase":"2","setting":"A Phase 2, Open-label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma","sponsor":"Takeda","started":"2021-11-12","startedType":"actual","yearReported":2025,"enrolled":27,"enrolledBasis":"registry","outcomes":[{"endpoint":"Number of Participants With Treatment Emergent Adverse Events (TEAEs)","primary":true,"unit":"participants","arms":[{"name":"Dose Escalation: TAK-007 - 200×10^6 CD19-CAR+ Viable NK Cells","n":3,"value":3,"note":"Figures from the ClinicalTrials.gov results section (first posted 2025-08-12), not from a publication"},{"name":"Dose Escalation: TAK-007 - 800×10^6 CD19-CAR+ Viable NK Cells","n":6,"value":6},{"name":"Dose Expansion: Cohort 1 (LBCL 3L+): TAK-007 - 800×10^6 CD19-CAR+ Viable NK Cells","n":10,"value":10},{"name":"Dose Expansion: Cohort 2 (iNHL 3L+): TAK-007 - 800×10^6 CD19-CAR+ Viable NK Cells","n":7,"value":7}],"source":"https://clinicaltrials.gov/study/NCT05020015?tab=results"},{"endpoint":"Overall Survival (OS)","unit":"months","arms":[{"name":"Dose Escalation: TAK-007 - 200×10^6 CD19-CAR+ Viable NK Cells","n":3,"value":8.9,"note":"range 1.7 to 20.3; Figures from the ClinicalTrials.gov results section (first posted 2025-08-12), not from a publication"},{"name":"Dose Escalation: TAK-007 - 800×10^6 CD19-CAR+ Viable NK Cells","n":6,"note":"Median was not estimable due to insufficient number of participants with events."},{"name":"Dose Expansion: Cohort 1 (LBCL 3L+): TAK-007 - 800×10^6 CD19-CAR+ Viable NK Cells","n":10,"value":8.4,"note":"range 0.9 to 11.2"},{"name":"Dose Expansion: Cohort 2 (iNHL 3L+): TAK-007 - 800×10^6 CD19-CAR+ Viable NK Cells","n":7,"note":"Median was not estimable due to insufficient number of participants with events."}],"source":"https://clinicaltrials.gov/study/NCT05020015?tab=results"},{"endpoint":"Progression-free Survival (PFS) Per Investigator","unit":"months","arms":[{"name":"Dose Escalation: TAK-007 - 200×10^6 CD19-CAR+ Viable NK Cells","n":3,"value":0.95,"note":"range 0.85 to 1.02; Figures from the ClinicalTrials.gov results section (first posted 2025-08-12), not from a publication"},{"name":"Dose Escalation: TAK-007 - 800×10^6 CD19-CAR+ Viable NK Cells","n":6,"value":2.23,"note":"range 0.95 to 9.00"},{"name":"Dose Expansion: Cohort 1 (LBCL 3L+): TAK-007 - 800×10^6 CD19-CAR+ Viable NK Cells","n":10,"value":2,"note":"range 0.03 to 5.55"},{"name":"Dose Expansion: Cohort 2 (iNHL 3L+): TAK-007 - 800×10^6 CD19-CAR+ Viable NK Cells","n":7,"value":5.62,"note":"range 2.83 to 8.77"}],"source":"https://clinicaltrials.gov/study/NCT05020015?tab=results"}]},"route":"/trials/nct05020015/","neighbours":{"cancer":[{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"company":[{"id":"takeda","kind":"company","name":"Takeda","route":"/companies/takeda/"}]}}